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Case Report Template  
 
 
 
• All case reports MUST be submitted online using this template. 
• Tables, images and multimedia files must be uploaded separately on submission. 
• Articles should be no more than 2,000 words in length and include a maximum of 10 
references. 
• It is essential that you list the learning points of the case; these are the messages that 
readers should remember when dealing with their own patients. 
• You must have signed informed consent from patients (or relatives/guardians) prior to 
publication, using our consent form. If the patient is dead, the consent form is not required. 
• EDM Case Reports is an open access publication. Expenses such as peer review systems, 
journal production, online hosting, marketing and archiving are covered by a publishing fee. 
The publishing fee will only become payable upon acceptance of a manuscript and needs to be 
paid for an article to proceed to publication.  
 
Publishing fees:  
• The standard publishing fee for accepted articles is £350.  
• Individual members of endorsing societies enjoy a special publishing fee of just £280. 
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Summary 
 
A 48-year old man was diagnosed with a large macroprolactinoma in 1982 treated with surgery, 
adjuvant radiotherapy and bromocriptine. Normal prolactin was achieved in 2005 but in 2009 it 
started rising. Pituitary MRIs in 2009, 2012, 2014 and 2015 were reported as showing empty 
pituitary fossa. Prolactin continued to increase (despite increasing bromocriptine dose). Trialling 
cabergoline had no effect (prolactin 191,380 mU/L). In January 2016, he presented with right facial 
weakness and CT head was reported as showing no acute intracranial abnormality. In late 2016, 
he was referred to ENT with hoarse voice; left hypoglossal and recurrent laryngeal nerve palsies 
were found. At this point, prolactin was 534,176 mU/L. Just before further endocrine review, he had 
a fall and CT head showed a basal skull mass invading the left petrous temporal bone. Pituitary 
MRI revealed a large enhancing mass within the sella infiltrating the clivus, extending into the left 
petrous apex and occipital condyle with involvement of the left Meckel’s cave, internal acoustic 
meatus, jugular foramen and hypoglossal canal. At that time, left abducens nerve palsy was also 
present. CT thorax/abdomen/pelvis excluded malignancy. Review of previous images suggested 
that this lesion had started becoming evident below the fossa in pituitary MRI of 2015. 
Temozolomide was initiated. After 8 cycles, there is significant tumour reduction with prolactin 
1565 mU/L and cranial nerve deficits have remained stable.  
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Prolactinomas can manifest aggressive behaviour even decades after initial treatment highlighting 
the unpredictable clinical course they can demonstrate and the need for careful imaging review. 
 
Learning points  
 
• Aggressive behaviour of prolactinomas can manifest even decades after first treatment 
highlighting the unpredictable clinical course these tumours can demonstrate. 
• Escape from control of hyperprolactinaemia in the absence of sellar adenomatous tissue 
requires careful and systematic search for the anatomical localization of the lesion 
responsible for the prolactin excess. 
• Temozolomide is a valuable agent in the therapeutic armamentarium for aggressive/invasive 
prolactinomas, particularly if they are not amenable to other treatment modalities. 
 
Background  
 
Dopamine agonists (DAs) are an effective treatment for patients with macroprolactinoma leading to 
normalisation of prolactin (PRL) and tumour shrinkage in 66-100% and 64-96% of the cases, 
respectively (1). Secondary resistance to these agents is rare and is manifested with often 
substantial increases in PRL levels and tumour enlargement (2).  
 
In cases non-responsive to DAs, the most commonly applied management options include 
changing to another DA, surgery and radiotherapy (alone or in combination) (3). In the last years, 
temozolomide has been added in the therapeutic armamentarium for unresponsive to conventional 
treatments prolactinomas (4).  
 
We herein report a rare case of an 81-year old male with a history of macroprolactinoma previously 
treated by surgery, radiotherapy and DA which more than 20 years after initial therapy and after 
having achieved normal PRL, demonstrated aggressive behaviour with significant 
hyperprolactinaemia and uncommon symptomatology (left recurrent laryngeal, hypoglossal and 
abducens nerve palsies) due to tumour invasion. In this patient, treatment with temozolomide led to 
biochemical and imaging response.  
 
Case presentation 
 
In 1982, a 48-year old man was admitted to hospital with worsening headaches (over four months) 
and diplopia (noticed two days prior to admission). Ophthalmology review showed reduced visual 
acuity bilaterally, left 3rd cranial nerve palsy and papilloedema. Plain skull X ray reported 
“destruction of the pituitary fossa and erosion of the left sphenoid wing”. CT of head disclosed a 
“middle fossa tumour occupying the tentorial hiatus and medial edge of the tentorium”. He was 
then transferred to the neurosurgical ward where it was decided to undergo craniotomy for urgent 
decompression and for establishing a pathological diagnosis. Based on the pathology report, 
histological diagnosis was not certain and the specimen could represent a pituitary tumour. At that 
time, the neurosurgical team referred the patient for radiotherapy which was completed two months 
later. Involvement of the endocrine team took place after these interventions and serum prolactin 
was found at 600,000 mU/L; furthermore, review of the pathology slides confirmed a chromophobe 
adenoma with positive immunostaining for PRL. The patient was started on bromocriptine on a 
final dose of 7.5 mg daily which led to a dramatic reduction of the PRL within a few months and 
levels of 2,500 mU/L 1.5 year later. He remained under long-term follow up and was maintained on 
bromocriptine (7.5 mg daily) and replacement with testosterone, hydrocortisone and levothyroxine. 
Normal serum PRL was finally achieved in 2005 (109 mU/L, reference range 40-360 mU/L) whilst 
on bromocriptine 2.5 mg daily (on this dose for around one year), but this began to rise in 2009 
(2,421 mIU/L). The patient had confirmed compliance with the DA treatment.  
 
At around this time, his prostate specific antigen (PSA) also began to rise.  He was referred to the 
urology team who diagnosed prostatic adenocarcinoma (Gleeson score 3+3). He was placed 
under active surveillance and testosterone therapy was stopped. 
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Investigations 
 
Pituitary MRIs performed in 2009, 2012, 2014 and 2015 were reported as showing empty pituitary 
fossa. However, serum PRL continued to rise significantly (despite increasing the dose of 
bromocriptine) reaching the value of 108,274 mU/L in 2015. Trialling cabergoline (up to 3 mg 
weekly) had no effect with the PRL measured at 191,380 mU/L a few months later. 
 
In January 2016, he presented to the Emergency Department with right facial weakness and CT 
head was reported as showing “no acute intracranial abnormality”. In a subsequent neurology 
review, the diagnosis of a transient ischaemic attack was thought unlikely but concerns were raised 
about the presence of manifestations of cerebellar ataxia.  Review of the brain images, suggested 
significant cerebellar atrophy and the most likely cause of the ataxia was then considered to be the 
previous radiotherapy. 
 
In late 2016, he was referred to an ENT team with a hoarse voice and was found to have left 
hypoglossal and left recurrent laryngeal nerve palsy.  The possibilities of prolactinoma extension to 
the skull base or a new skull base tumour were raised. At this point, his serum PRL had reached a 
peak of 534,176 mU/L (on bromocriptine 15 mg daily) but just before further endocrine review and 
imaging were performed, he had a fall for which he had CT head. This disclosed a basal skull 
mass invading the left petrous temporal bone. A subsequent pituitary MRI showed a large 
enhancing mass lesion within the sella infiltrating the clivus, extending into the left petrous apex 
and occipital condyle with involvement of the left Meckel’s cave, internal acoustic meatus, jugular 
foramen and hypoglossal canal (Figures 1 and 2). At that time, left abducens nerve palsy had been 
added in his symptomatology. A CT thorax, abdomen and pelvis excluded malignancy and 
throughout this period, his PSA was undetectable. Review of previous images suggested that this 
lesion had started becoming evident below the fossa in the pituitary MRI performed in 2015 (as an 
area of low attenuation in the clivus which in the latest MRI had increased around three times in 
maximum diameter). An invasive prolactinoma demonstrating aggressive behaviour and not 
responding to DA treatment was considered the diagnosis in this case.  
 
Treatment  
 
Following discussion of the patient’s case in the Pituitary Multidisciplinary Team meeting and 
taking into account the imaging appearances of the tumour, the presence of ataxia and the 
performance status of the patient (PS 2), surgery and repeat radiotherapy were not considered 
appropriate management options and treatment with temozolomide was suggested. This was 
initiated in July 2017 (150 mg/m2 per os for five days increasing to 200 mg/m2 repeated every four 
weeks). 
 
Outcome and follow-up   
 
After three cycles of temozolomide, pituitary MRI demonstrated tumour volume reduction (Figures 
3 and 4) and his serum PRL had fallen to 23,132 mIU/L. His cranial nerve deficits have remained 
stable and he is tolerating temozolomide well, with his main side effect being fatigue.  
He is under regular Oncology, Endocrinology, and Neurology follow-up and his latest PRL (after 
nine cycles) was at 1565 mU/L. A total of 12 temozolomide cycles have been planned. Further 
decisions on extending the duration of treatment will be taken after the completion of the planned 
therapy and the review of tumour response.  
 
Discussion  
 
 
We have presented a rare case of a large macroprolactinoma treated with surgery, radiotherapy 
and DA which 27 years after initial therapy and four years after the achievement of normal PRL 
showed escape from control with a continuous dramatic rise in the PRL levels and invasion of 
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surrounding structures causing palsies of left VI, X, XII cranial nerves. The tumour was not 
responsive to DA treatment and temozolomide was initiated with good biochemical/imaging 
response.  
 
In our case, prolactinoma control was initially achieved following a multimodality approach. In a 
multicentre study of 92 patients with DA resistant prolactinomas offered various treatment 
approaches (DA, surgery, radiotherapy), normal PRL was observed in 28% (26 out of 92 patients; 
8 treated exclusively with DA and 18 with DA and surgery or DA and surgery and radiotherapy), 
adenoma disappearance in 18%, and adenoma progression in 15% of the cases during a median 
follow-up period of 88 months (3). Overall, 4% of the patients had locally aggressive tumours and 
3% developed pituitary carcinoma (with the metastatic disease diagnosed 10-22 years after tumour 
evolution); notably, overall mortality was 4% due to pituitary carcinomas or neurological 
complications associated with a rapidly growing tumour (3).  
 
Our patient retained normal PRL for a period of four years (during which he had remained on 
bromocriptine), with the tumour developing aggressive behaviour thereafter and finally presenting 
with left recurrent laryngeal, hypoglossal and abducens nerve palsies; to our knowledge, such 
symptomatology has not been reported before. The mechanisms triggering the loss of control and 
the transformation of tumour phenotype have not been elucidated. 
 
Secondary resistance to DA treatment is a rare phenomenon and presents with an increase in PRL 
levels and often rapid growth/invasion of the prolactinoma. The real prevalence is unknown and the 
relevant published literature is limited with only a few cases available (2,5).  Before this diagnosis 
is established, non-compliance to DA needs to be excluded. The pathogenetic mechanisms are not 
clear and, interestingly, development of late loss of responsiveness to DA has been related with 
the initiation of gonadal hormone replacement (1). Based on the published literature, the interval 
for the diagnosis of secondary resistance ranges between 10 months to 15 years (2) and the 
patients had presented with headache and blurred vision (2), persistent galactorrhoea (6), 
asymptomatic rise in PRL concentration (6,7) or progression on imaging (8). Notably, secondary 
resistance has more often been reported in the setting of malignant transformation of a 
prolactinoma necessitating careful clinical and imaging assessment (9).   
 
In our patient, repeat surgery and/or radiotherapy were not considered as appropriate 
management strategy and temozolomide was offered. The outcome following the first three cycles 
was promising with tumour shrinkage and significant reduction in his PRL levels; the optimal 
response was further confirmed in his latest follow-up nine months after the initiation of 
temozolomide. Temozolomide, an alkylating oral chemotherapy agent acting via DNA methylation 
to induce DNA fragmentation is typically dosed at 150–200 mg/m2 for five days in 28-day cycles; 
several studies have demonstrated that lack of response after three cycles, either in tumour size or 
PRL levels, is predictive of a poor outcome (10,11). Review of the literature of case series 
including five or more patients with pituitary adenomas or carcinomas treated with this agent (9-12 
cycles) has shown complete or partial radiological response in 42% and stable disease in 27% of 
them; the response rate in prolactinomas was 44%. Unlike for malignant gliomas, the data on the 
value of MGMT (Methylguanine-DNA methyltransferase) or of the mismatch repair protein MSH6 
tumour status on predicting temozolomide responsiveness are not entirely clear; it should be noted 
however, that although MGMT expression measured by PCR-based methods has not been 
associated with response to temozolomide, low MGMT content determined by 
immunohistochemistry is mostly related with positive response to this agent (11). The optimum 
duration of temozolomide treatment remains uncertain, as does the durability of response following 
cessation of treatment. Notably, recurrence after cessation of this treatment has been reported in 
27-67% of the patients with various types of pituitary adenomas and variable follow-up duration, 
with progression free survival ranging between 8-12 months (12).   
 
Interestingly, during his follow-up, our patient was diagnosed with prostatic adenocarcinoma 
leading to withdrawal of testosterone replacement. Berinder et al. in population-based matched 
cohort study in Sweden found reduced prostate cancer risk in males with hyperprolactinaemia (13). 
The authors suggested that this may be attributed to the history of low androgen exposure as a 
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result of the hyperprolactinaemia-induced hypogonadism. On the other hand, when testosterone 
replacement is offered to these patients, PSA is monitored more systematically, potentially leading 
to increased rates of prostate cancer diagnosis and possible bias in the estimation of prostate 
carcinoma incidence in this group of patients.  
 
Our case represents a rare clinical course of a patient with macroprolactinoma with a remarkably 
late escape from control and demonstration of invasive/aggressive behaviour, highlights pitfalls in 
the identification of non-sellar aggressive adenomatous tissue and enhances the value of 
temozolomide in the management algorithm of such challenging cases.  
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Figure 1: June 2017, Coronal and sagittal Post-contrast T1 images showing mass infiltrating the 
clivus with extension into the left petrous apex and occipital condyle.  
 
 
Figure 2: June 2017, Axial post-contrast T1 images. Note lateral extension into the clivus and 
occiput.  
 
 
Figure 3: October 2017, Coronal and sagittal post-contrast T1 images after three cycles of 
temozolomide showing significant response to treatment on residual disease involving clivus, left 
petrous apex  Meckel's cave, jugular foramen and hypoglossal canal. 
 
 
Figure 4: October 2017, Axial post-contrast T1 images after three cycles of temozolomide. 
 
Patient’s perspective 
 
 
